Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others
about
Why the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard ItemIndustry sponsorship and research outcomeAssociation between personal conflicts of interest and recommendations on medical interventionsGalactomannan detection for invasive aspergillosis in immunocompromized patientsAssociation of trial registration with the results and conclusions of published trials of new oncology drugsIndustry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statinsThe cycle of bias in health research: a framework and toolbox for critical appraisal trainingOutcome reporting among drug trials registered in ClinicalTrials.gov'To prove this is the industry's best hope': big tobacco's support of research on the genetics of nicotine addictionCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsResearch Misconduct: The Peril of Publish or PerishSystematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancerUse of a modified GreenScreen tool to conduct a screening-level comparative hazard assessment of conventional silver and two forms of nanosilverFactors associated with results and conclusions of trials of thiazolidinedionesComparative effectiveness research: an empirical study of trials registered in ClinicalTrials.govImpact of reporting bias in network meta-analysis of antidepressant placebo-controlled trialsNonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysisStrategies for obtaining unpublished drug trial data: a qualitative interview studyWhy we need easy access to all data from all clinical trials and how to accomplish itAdjustment for reporting bias in network meta-analysis of antidepressant trials.Reporting science and conflicts of interest in the lay press.CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration.Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusionsRelationship between sponsorship and failure rate of dental implants: a systematic approach.Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews.The Navigation Guide systematic review methodology: a rigorous and transparent method for translating environmental health science into better health outcomesCoauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysisReporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study.Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.The Relationship between Risk of Bias Criteria, Research Outcomes, and Study Sponsorship in a Cohort of Preclinical Thiazolidinedione Animal Studies: A Meta-AnalysisDoes family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: no.Endpoint selection and relative (versus absolute) risk reporting in published medication trials.Medical reversal: why we must raise the bar before adopting new technologiesReporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort studyEvidence from Toxicology: The Most Essential Science for Prevention
P2860
Q24201550-9D676458-05F1-4E55-872F-3381057BD9B8Q24202591-17A18153-2549-42B0-8C50-A565F8772BC8Q24202627-B2DBD37E-E6B2-4D70-B3FD-E1CC68165B3CQ24240734-D893FC00-6365-4F8D-8E96-5E5EFB0567FEQ24288921-2B52AACD-A5AF-4B36-984E-D04B4E9D4FF9Q24289041-C775030C-45D2-4B64-8795-950F27295ED2Q24289237-84E4FA66-CEF2-4433-B8D6-1D069915E8AFQ24289273-24535D1F-AF78-4E21-B641-9E77D108EA29Q24601455-404519F3-7B4B-4047-984E-2E7036BD753FQ24614627-31F327C4-B127-4275-9601-186ABBEBCFFCQ26774042-E36FB397-9C3D-4C68-A2E0-792B6456CBEAQ27008416-AE8972A1-EF68-43D4-B0DD-C038AAC15ACAQ28393577-D6FC07EF-9238-48AB-B90B-9EB4286736C8Q28475588-79A39429-78EA-417C-A645-CA92FFF18F25Q28478742-DE518E16-49E4-4B68-BF4F-8D73C606BC41Q28482475-4D8B9DAA-DFAB-4795-B7EB-5431DE45FDA1Q28538894-E4C732C6-5BA2-423A-B7F4-BFAB2526A5C8Q28681320-0B6F3DC7-CDF3-4730-8892-8EAE4D32D5EBQ28732492-922963EC-21A6-4B50-B739-BEF5EB1AD888Q31100974-D6561C39-EE8C-4577-9CC4-8CC448409174Q33308724-022448A8-73AA-4BA5-BDC1-EC3D7A8011FAQ33316156-8453AD96-B463-46AB-9E71-40E8FB1769CCQ33364538-F5BB5ADC-2696-4AAB-B17C-04BA497722BCQ33368267-EC9C3EBB-A546-45F7-BA8F-095872BD098DQ33565529-38D72F3E-38FE-4590-A261-4E06674A4E7CQ34025773-19D9A590-03BC-44C7-9EE6-372CEB5BB419Q34047368-C4C2BA80-5127-4B36-8EC0-2DE32D44B784Q34275302-244C7E7B-805B-450C-A067-D13AD809C07BQ34292774-33B19188-F14F-4E38-9011-31A80412707EQ34294990-1070A011-4767-41E2-B3AF-0F124D3FBCEAQ34483629-9331FFE5-A47D-420D-ADA6-EA0F186DCD1EQ34728162-3CFF4CB8-E77C-442C-AE49-663221D81108Q34828582-EB6CD3DB-9686-4BED-A926-D5C85765CEE3Q35012566-A6BF9EB8-D5E8-4F26-9F0A-B3A667D72957Q35162384-22985059-2BB2-4CC8-80F8-AD725888369BQ35527067-40B34408-7C30-4011-A2D9-D464922C7AC5Q35614816-66038E53-237E-453D-BAF6-84052729DB61Q36104646-776C1D40-DA2B-45C4-993E-34D38B8E05A8Q36248519-9C0E4E39-8ADF-467C-AAEE-7B86221233C0Q36456218-9DFF0317-9189-4EE0-A96D-CA7AF9F3CE70
P2860
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Factors associated with findin ...... r more efficacious than others
@ast
Factors associated with findin ...... r more efficacious than others
@en
Factors associated with findin ...... r more efficacious than others
@en-gb
Factors associated with findin ...... r more efficacious than others
@nl
type
label
Factors associated with findin ...... r more efficacious than others
@ast
Factors associated with findin ...... r more efficacious than others
@en
Factors associated with findin ...... r more efficacious than others
@en-gb
Factors associated with findin ...... r more efficacious than others
@nl
altLabel
Factors Associated with Findin ...... r More Efficacious than Others
@en
prefLabel
Factors associated with findin ...... r more efficacious than others
@ast
Factors associated with findin ...... r more efficacious than others
@en
Factors associated with findin ...... r more efficacious than others
@en-gb
Factors associated with findin ...... r more efficacious than others
@nl
P2093
P2860
P3181
P1433
P1476
Factors associated with findin ...... r more efficacious than others
@en
P2093
Fieke Oostvogel
Peter Bacchetti
P2860
P3181
P356
10.1371/JOURNAL.PMED.0040184
P407
P50
P577
2007-06-01T00:00:00Z